Top

Published in:

11-04-2024 | Urothelial Cancer | REVIEW

Management of Oligometastatic and Locally Recurrent Urothelial Carcinoma

Authors: Michael A. Liu, Jennifer W. Li, Karie Runcie

Published in: Current Oncology Reports | Issue 5/2024

Abstract

Purpose of Review

To summarize and evaluate the literature on treatment approaches for oligometastatic and locally recurrent urothelial cancer.

Recent Findings

There is no clear definition for oligometastatic urothelial cancers due to limited data. Studies focusing on oligometastatic and locally recurrent urothelial cancer have been primarily retrospective. Treatment options include local therapy with surgery or radiation, and generalized systemic therapy such as chemotherapy or immunotherapy.

Summary

Oligometastatic and locally recurrent urothelial cancers remain challenging to manage, and treatment requires an interdisciplinary approach. Systemic therapy is nearly always a component of current care in the form of chemotherapy, but the role of immunotherapy has not been explored. Consideration of surgical and radiation options may improve outcomes, and no studies have compared directly between the two localized treatment options. The development of new prognostic and predictive biomarkers may also enhance the treatment landscape in the future.

Amin HAA, Kobaisi MH, Samir RM. Schistosomiasis and bladder cancer in Egypt: truths and myths. Open Access Maced J Med Sci. 2019;7(23):4023–9. https://doi.org/10.3889/oamjms.2019.857.CrossRefPubMedPubMedCentral

Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10. https://doi.org/10.1200/jco.1995.13.1.8.CrossRefPubMed

Ogihara K, Kikuchi E, Watanabe K, Kufukihara R, Yanai Y, Takamatsu K, et al. Can urologists introduce the concept of “oligometastasis” for metastatic bladder cancer after total cystectomy? Oncotarget. 2017;8(67):111819–35. https://doi.org/10.18632/oncotarget.22911.CrossRefPubMedPubMedCentral

Franzese C, Francolini G, Nicosia L, Alongi F, Livi L, Scorsetti M. Stereotactic body radiation therapy in the management of oligometastatic and oligoprogressive bladder cancer and other urothelial malignancies. Clin Oncol (R Coll Radiol). 2021;33(1):50–6. https://doi.org/10.1016/j.clon.2020.07.008.CrossRefPubMed

Bamias A, Stenzl A, Brown SL, Albiges L, Babjuk M, Birtle A, et al. Definition and diagnosis of oligometastatic bladder cancer: a Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty. Eur Urol. 2023

Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Choueiri TK, Necchi A, et al. Improved 5-factor prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma. J Urol. 2016;195(2):277–82. https://doi.org/10.1016/j.juro.2015.07.111.CrossRefPubMed

Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 2010;28(11):1850–5. https://doi.org/10.1200/jco.2009.25.4599.CrossRefPubMed

Petrelli F, Ghidini A, Ghidini M, Bukovec R, Trevisan F, Turati L, et al. Better survival of patients with oligo-compared with polymetastatic cancers: a systematic review and meta-analysis of 173 studies. F1000Res. 2021;10

Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, et al. Bladder cancer, Version 3.2020. NCCN Clinical Practice Guidelines in Oncology J Natl Compr Canc Netw. 2020;18(3):329–54. https://doi.org/10.6004/jnccn.2020.0011.CrossRefPubMed

10.

Pisters LL, Westney L. The management of locally recurrent invasive bladder cancer following radical cystectomy. Semin Urol Oncol. 1996;14(2):112–9.PubMed

11.

Westney OL, Pisters LL, Pettaway CA, Tu SM, Pollack A, Dinney CP. Presentation, methods of diagnosis and therapy for pelvic recurrence following radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 1998;159(3):792–5.CrossRefPubMed

12.

Stein JP, Lieskovsky G, Cote R, Groshen S, Feng A-C, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2023;41(22):3772–81.CrossRefPubMed

13.

Mitra AP, Quinn DI, Dorff TB, Skinner EC, Schuckman AK, Miranda G, et al. Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. BJU Int. 2012;109(6):846–54. https://doi.org/10.1111/j.1464-410X.2011.10455.x.CrossRefPubMed

14.

Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser Hr, Markwalder R, et al. Radical cystectomy for bladder cancer today—a homogeneous series without neoadjuvant therapy. J Clin Oncol. 2003; 21(4):690–6

15.

Cagiannos I, Morash C. Surveillance strategies after definitive therapy of invasive bladder cancer. Can Urol Assoc J. 2009;3(6 Suppl 4):S237–42. https://doi.org/10.5489/cuaj.1205.CrossRefPubMedPubMedCentral

16.

Bochner BH, Montie JE, Lee CT. Follow-up strategies and management of recurrence in urologic oncology bladder cancer: invasive bladder cancer. Urol Clin North Am. 2003;30(4):777–89. https://doi.org/10.1016/s0094-0143(03)00061-2.CrossRefPubMed

17.

Zehnder P, Studer UE, Skinner EC, Thalmann GN, Miranda G, Roth B, et al. Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades. BJU Int. 2013;112(2):E51–8. https://doi.org/10.1111/bju.12215.CrossRefPubMed

18.

Abe T, Minami K, Harabayashi T, Sazawa A, Chiba H, Kikuchi H, et al. Prognostic impact of local radiotherapy on metastatic urothelial carcinoma patients receiving systemic chemotherapy. Jpn J Clin Oncol. 2020;50(2):206–13. https://doi.org/10.1093/jjco/hyz152.CrossRefPubMed

19.

Faltas BM, Gennarelli RL, Elkin E, Nguyen DP, Hu J, Tagawa ST. Metastasectomy in older adults with urothelial carcinoma: population-based analysis of use and outcomes. Urol Oncol. 2018;36(1):9.e11-9.e7. https://doi.org/10.1016/j.urolonc.2017.09.009.CrossRefPubMed

20.

Siefker-Radtke AO, Walsh GL, Pisters LL, Shen Y, Swanson DA, Logothetis CJ, et al. Is there a role for surgery in the management of metastatic urothelial cancer? The M D Anderson experience. J Urol. 2004;171(1):145–8. https://doi.org/10.1097/01.ju.0000099823.60465.e6.CrossRefPubMed

21.

Iwamoto H, Izumi K, Shimura Y, Natsagdorj A, Maolake A, Takezawa Y, et al. Metastasectomy improves survival in patients with metastatic urothelial carcinoma. Anticancer Res. 2016;36(10):5557–61. https://doi.org/10.21873/anticanres.11140.CrossRefPubMed

22.

Muilwijk T, Akand M, Van der Aa F, Dumez H, De Meerleer G, Van Raemdonck D, et al. Metastasectomy of oligometastatic urothelial cancer: a single-center experience. Transl Androl Urol. 2020;9(3):1296–305. https://doi.org/10.21037/tau-19-624.CrossRefPubMedPubMedCentral

23.

Pastorino U, Buyse M, Friedel G, Ginsberg RJ, Girard P, Goldstraw P, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997;113(1):37–49. https://doi.org/10.1016/s0022-5223(97)70397-0.CrossRefPubMed

24.

Zaghloul MS. Adjuvant and neoadjuvant radiotherapy for bladder cancer: revisited. Future Oncol. 2010;6(7):1177–91. https://doi.org/10.2217/fon.10.82.CrossRefPubMed

25.

Chalkidou A, Macmillan T, Grzeda MT, Peacock J, Summers J, Eddy S, et al. Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. Lancet Oncol. 2021;22(1):98–106. https://doi.org/10.1016/s1470-2045(20)30537-4.CrossRefPubMed

26.•

Aboudaram A, Chaltiel L, Pouessel D, Graff-Cailleaud P, Benziane-Ouaritini N, Sargos P, et al. Consolidative radiotherapy for metastatic urothelial bladder cancer patients with no progression and with no more than five residual metastatic lesions following first-line systemic therapy: a retrospective analysis. Cancers (Basel). 2023. 15(4). https://doi.org/10.3390/cancers15041161. This recent article is the largest retrospective study on radiotherapy for oligometastatic urothelial cancer, consisting of 91 patients from four comprehensive cancer centers from 2005 to 2018, which demonstrated a large overall (HR 0.47) and progression free (HR 0.49) survival benefit.

27.

Francolini G, Desideri I, Detti B, Di Cataldo V, Masi L, Caramia G, et al. Stereotactic radiotherapy in oligoprogressive and oligorecurrent urothelial cancer patients: a retrospective experience. Cancer Treat Res Commun. 2019;19:100124. https://doi.org/10.1016/j.ctarc.2019.100124.CrossRefPubMed

28.

Augugliaro M, Marvaso G, Ciardo D, Zerini D, Riva G, Rondi E, et al. Recurrent oligometastatic transitional cell bladder carcinoma: is there room for radiotherapy? Neoplasma. 2019;66(1):160–5. https://doi.org/10.4149/neo_2018_180522N333.CrossRefPubMed

29.

Nevens D, Jongen A, Kindts I, Billiet C, Deseyne P, Joye I, et al. Completeness of reporting oligometastatic disease characteristics in the literature and influence on oligometastatic disease classification using the ESTRO/EORTC nomenclature. Int J Radiat Oncol Biol Phys. 2022;114(4):587–95. https://doi.org/10.1016/j.ijrobp.2022.06.067.CrossRefPubMed

30.

Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218–30. https://doi.org/10.1056/NEJMoa2002788.CrossRefPubMed

31.

Leonetti A, D’Abbiero N, Baldari G, Andreani S, Ruffini L, Viansone AA, et al. Radiotherapy for the treatment of distant nodes metastases from oligometastatic urothelial cancer: a retrospective case series. Int J Urol. 2018;25(10):879–86. https://doi.org/10.1111/iju.13773.CrossRefPubMed

32.

Powles TB, Perez Valderrama B, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. LBA6 EV-302/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Ann Oncol. 2023;34:S1340. https://doi.org/10.1016/j.annonc.2023.10.106.CrossRef

33.

van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, et al. Nivolumab plus gemcitabine–cisplatin in advanced urothelial carcinoma. N Engl J Med. 2023;389(19):1778–89. https://doi.org/10.1056/NEJMoa2309863.CrossRefPubMed

34.

Herr HW, Faulkner JR, Grossman HB, Natale RB, deVere WR, Sarosdy MF, et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol. 2004;22(14):2781–9. https://doi.org/10.1200/jco.2004.11.024.CrossRefPubMed

35.

Fischer-Valuck BW, Michalski JM, Mitra N, Christodouleas JP, DeWees TA, Kim E, et al. Effectiveness of postoperative radiotherapy after radical cystectomy for locally advanced bladder cancer. Cancer Med. 2019;8(8):3698–709. https://doi.org/10.1002/cam4.2102.CrossRefPubMedPubMedCentral

36.

Wishnow KI, Dmochowski R. Pelvic recurrence after radical cystectomy without preoperative radiation. J Urol. 1988;140(1):42–3. https://doi.org/10.1016/s0022-5347(17)41480-7.CrossRefPubMed

37.•

Ballas L, Wei O, Daneshmand S, Schuckman A, Djaladat H, Aron M, et al (2020) Chemoradiation for management of locally recurrent or residual bladder cancer: a case series and review of the literature Clin Genitourin Cancer 18 4 e473-e7. https://doi.org/10.1016/j.clgc.2019.12.016. This recent article involving a case series of five patients with locally recurrent urothelial cancer is the first to demonstrate the potential safety and efficacy of locoregional chemoradiation treatment in this setting.

Title: Management of Oligometastatic and Locally Recurrent Urothelial Carcinoma
Authors: Michael A. Liu
Jennifer W. Li
Karie Runcie
Publication date: 11-04-2024
Publisher: Springer US
Keywords: Urothelial Cancer
Urothelial Cancer
Systemic Therapy
Cystectomy
Cytostatic Therapy
Systemic Therapy
Bladder Cancer
Bladder Cancer
Published in: Current Oncology Reports / Issue 5/2024
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-024-01523-8

Ablation of Kidney Tumors in Patients with Substantial Kidney Impairment: Current Status

Chronic Kidney Disease
REVIEW

Novel therapies for glioblastoma

Glioblastoma
Review

Perioperative Neurocognitive Function in Glioma Surgery

Glioma
REVIEW

Patient Navigation in Cancer Treatment: A Systematic Review

Open Access
REVIEW

Advances in radionuclide therapies for neuroendocrine tumors

Open Access
Neuroendocrine Tumor
Review

Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer

Prostate Cancer
REVIEW

Women’s health knowledge hub

Menopause
Clinical Collection

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Genetic Testing
On-demand Webinar

In this interactive webinar, experts Dr. Subbiah, Dr. Drilon, and Dr. Williams discuss best pathological practices within NSCLC and thyroid cancer, as well as how genomic testing can improve outcomes in clinical practice, using patient case studies as illustrations.

This content is intended only for US-based healthcare providers.

Supported by:

Illumina, Inc., and Eli Lilly and Company

Dr. Vivek Subbiah

Dr. Alexander Drilon

Dr. Michelle Williams

Developed by: Springer Healthcare

Watch now

Elevate your expertise in aplastic anemia (Link opens in a new window)

Aplastic Anemia
Independent Medical Education

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases.

Supported by:

Pfizer

Developed by: Springer Healthcare IME

Learn more

Navigating neuroimaging in Alzheimer disease care

Springer Medicine

Management of Oligometastatic and Locally Recurrent Urothelial Carcinoma

Abstract

Purpose of Review

Recent Findings

Summary

Other articles of this Issue 5/2024

Ablation of Kidney Tumors in Patients with Substantial Kidney Impairment: Current Status

Novel therapies for glioblastoma

Perioperative Neurocognitive Function in Glioma Surgery

Patient Navigation in Cancer Treatment: A Systematic Review

Advances in radionuclide therapies for neuroendocrine tumors

Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer

Women’s health knowledge hub

Incorporating comprehensive genomic profiling into the standard-of-care for NSCLC and thyroid cancer

Elevate your expertise in aplastic anemia (Link opens in a new window)

Navigating neuroimaging in Alzheimer disease care

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content